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Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder that carries large health and socioeconomic burdens. Current therapies
for PD are ultimately inadequate, both in terms of symptom control and in modification of disease progression. Deep brain
stimulation and infusion therapies are the current mainstay for treatment of motor complications of advanced disease, but these
have very significant drawbacks and offer no element of disease modification. In fact, there are currently no agents that are
established to modify the course of the disease in clinical use for PD. Gene and cell therapies for PD are now being trialled in the
clinic. These treatments are diverse and may have a range of niches in the management of PD. They hold great promise for
improved treatment of symptoms as well as possibly slowing progression of the disease in the right patient group. Here, we
review the current state of the art for these therapies and look to future strategies in this fast-moving field.
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Introduction
The long-held promise of gene and cell therapies (GCTs) for
Parkinson’s disease (PD) is slowly starting to emerge as a real-
istic prospect. In the last decade, the first in vivo gene therapies
(GTs) for non-neurological conditions have met regulatory ap-
proval initially in the form of Glybera in 2012 for hereditary
lipoprotein lipase deficiency. This was followed not long after
by Luxterna in 2018 for the eye disorder Leber’s congenital
amaurosis and Zolgensma in 2019 for spinal muscular atrophy
[1–3]. The conditions that these therapies are aimed at are how-
ever all rare (or “ultra-rare”), and for this reason, such GTs are
unlikely to be transformative to substantial healthcare sectors,
and their commercial viability has been questioned.
In contrast, PD is a relatively common neurodegenerative
disease that, owing to its debilitating long-term effects, carries
a large socioeconomic impact. As such, GCTs for PD could be
transformative not only for the disease itself but also for the
pharmaceutical economy.
Primarily a central nervous system (CNS) disorder, the
dominant effects of PD are on movement and cognition, and
in early disease motor features correlate tightly with degener-
ation of dopaminergic neuronal projections from the
substantia nigra pars compacta (SNc) to the striatum.
Therapeutic responses to pharmacological agents, such as oral
dopamine (DA) precursor medications (levodopa), are often
satisfactory in the early years after diagnosis, but become
steadily less efficacious as the disease progresses. Within
10 years of disease onset, the progression is such that re-
sponsiveness to levodopa and other oral dopaminergics is
unreliable, and additional DA unresponsive features may
begin to dominate the clinical picture. These features can
also be aggravated by side effects from the dopaminergic
therapies the patient is taking, for example postural hypo-
tension and neuropsychiatric problems.
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The problems faced in treating advanced disease, coupled
with the predictable progression and anatomically defined na-
ture of the underlying DA deficit, has led to the promotion of
GCTs as an attractive prospect for improved symptomatic
treatment of PD, and potentially also for disease modification.
Treatment Options in Advancing Disease
One of the main burdens of living with PD are the fluc-
tuations in motor performance that emerge and then wors-
en from 5 years after diagnosis, such that after 10 years of
the disease, 100% of patients have motor fluctuations, and
56% have levodopa-induced dyskinesias [4]. Loss of
striatal dopaminergic innervation is considered a major
factor in the development of these clinical features, and
DA replacement strategies that more successfully achieve
continuous exposure of striatal neurons to DA (such as
infusion therapies (IT)), rather than the inconsistent levels
provided by oral therapies, have demonstrated a clear
ability to smooth out these fluctuations.
The currently widely used ITs (reviewed in [5]) include the
following:
& Levodopa–carbidopa intestinal gel (LCIG [6–8]), which is
administered by a pump and catheter enterically
(intrajejunally), so bypassing gastric emptying.
& Apomorphine, an agonist for DA receptors, which can be
administered via subcutaneous infusion, so bypassing the
enteric system entirely [9].
Over the last 25 years, however, deep brain stimulation
(DBS) has risen rapidly to become the gold standard for
treating worsening motor fluctuations in patient who remain
levodopa responsive but free of the more severe gait and cog-
nitive issues of advanced PD [10]. By providing round the
clock electrical stimulation to the subthalamic nucleus
(STN), this technology acts to revert neuronal activity within
the movement circuitry from the abnormal pattern that arises
with DA depletion, to a pattern more typical of the DA replete
(“normal”) state [11]. Using different strategies, therefore,
both ITs and DBS achieve a smoother DA response than oral
therapies, with consequent beneficial effects on quality of life.
However, each of these options carries its own problems.
Apomorphine is frequently poorly tolerated due to side ef-
fects, cognitive issues, or local injection site problems.
LCIG, often used in patients too elderly or frail to consider
DBS, is prone to problems of delivery, for example relating to
tube dislodgement or blockage. DBS carries not only imme-
diate surgical risks, but also risks of stimulation-related speech
and swallowing difficulties and of device infection.Moreover,
each technology has very significant recurring expenses either
on a daily basis or in the form of infrequent but expensive
hardware maintenance and replacement for DBS.
A Gap in the Market
Although DBS technologies are still evolving, with promised
improvements in targeting, tuning of stimulus effect, and bat-
tery life [12], there is nonetheless a “gap in the market” that
gene and cell therapies (GCTs) are well placed to fill. An at-
tractive aspect of GCTs is their promise of a one-shot solution,
without the down sides and recurring costs of infusion therapies
and DBS. Additionally, by being targeted to the predominant
site of PD pathology, they may be less prone to the off-target
side effects seen with ITs and to a lesser extent with DBS. An
ultimately higher goal is the potential for GCTs to slow disease
progression, or even to repair aspects of the neurodegenerative
changes that occur in PD brain—for example, by using neuro-
nal cell therapies that can release DA in a normal synaptic
fashion where it is needed.
From the perspective of GCT technology development, PD
has both attractions and hurdles. On the plus side, it is
a common condition that is hugely costly to treat by conven-
tional means, and that is also increasingly well understood at a
pathological and anatomical level. On the other hand, both ITs
and DBS are now well-established and effective treatments,
meaning that the bar to improvement is high. As such, the
financial risks for companies trying to dethrone these proven
technologies are not trivial.
Vectors for Gene Therapy
Of the various viral vectors that have been investigated over
the years, two have emerged as worthy of translation into the
clinic for PD. These are adeno-associated viruses (AAVs) and
lentiviruses (LVs), and they will each be discussed separately.
AAV Vectors
Adeno-associated viruses have probably received the lion’s
share of attention for use as vectors for GT in PD. They are
small (4.7 kB), non-enveloped, single-stranded DNA viruses,
of the parvovirus family, and have been considered
as potential vectors for gene therapy for over two decades
[13–15]. As a family, they are able to infect a wide range of
tissues, including both neural and non-dividing cells [16, 17],
with long-term transcription of cargo sequences obtained epi-
somally, without integration into host genome [18, 19].
Multiple AAV serotypes exist and have varied tropism for
different species and cell populations, meaning different sero-
types have been used to target different tissues [20], with the
AAV2 serotype in particular showing robust and long-term
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neuronal expression in both animals and humans ([21–-
23], reviewed in [14, 24, 25]). The main drawbacks of AAVs
are the limited size of transgene they can carry, the ability to
upscale their manufacture, and also the theoretical issue of a
pre-existing immune response to them in some patients.
However, cargo size is only a challenge for certain GT strate-
gies (as will be discussed below), and new methods have now
largely resolved previous technical difficulties related to
manufacturing large quantities of high quality virus [20, 26].
The immunogenicity of AAVs however remains debated.
Although this has not so far emerged as a consistent problem
in the immune privileged CNS, it is recognized that AAVs can
provoke immune responses that vary with serotype and that
may limit the effectiveness of systemic treatments, or prevent
repeated dosing [27–29]. Where more serious immune re-
sponses have been reported in the brain in animal models, they
have been attributed to the non-native transgene in some cases
(e.g., intracerebroventricular injection AAV9 with green fluo-
rescent protein [30]). However, it is also possible that the
AAV9 serotype is particularly susceptible to detrimental side
effects under certain delivery conditions, possibly because of
its ability to transfect a wide variety of cells types. Thus,
intravenous and intracisternal delivery in animal models has
been reported to cause a sensory neuronopathy of variable
severity [28, 31, 32]. Interestingly, Perez et al. report that
use of species-specific transgene may prevent this outcome,
implying that an anti-transgene immune response may con-
tribute in some cases, but autoimmune and toxic causes have
also been speculated [28, 32]. The reports have been
concerning enough to put a halt to further use of the intrathecal
route for delivery of Zolgensma (AAV9) for spinal muscular
atrophy—a treatment that received licensing for human use
(intravenously) in 2019 [33, 34].
The use of AAV2 in PD has to date not found similar
issues, and this serotype has also been employed to carry the
RPE65 gene in Luxterna for eye disease (Leber’s congenital
amaurosis) [35–37]. It has also been used experimentally in
children, in treatment trials for the rare conditions AADC
deficiency [38] and Canavan’s leukodystrophy [39].
Meanwhile, AAV1 has been used in another approved GT,
Glybera, for hereditary lipoprotein lipase deficiency HLLD
(AAV1) [40].
Lentiviral Vectors
The second vector type in current use are lentiviruses. These
are markedly different to AAVs, being enveloped RNA retro-
viruses that obtain long-term expression through genomic in-
tegration. Retroviruses have long been used in the biological
sciences for non-clinical work, owing to their ease of manip-
ulation and also their stable, regulatable expression. The main
advantage of LVs over other retroviruses is their ability to
infect postmitotic cells, including neurons, which facilitates
their use as vectors for neurons in vitro. This has made them
attractive candidates for use in CNS diseases.
The best known lentivirus is the human immunodeficiency
virus (HIV), but the first to be taken forward towards human
GT use was a non-human LV, the equine infectious anemia
virus (EIAV). This was engineered to include minimal viral
sequences, with proteins required for making up the viral par-
ticle (Gag) and replicatory enzymes (Pol) being supplied “in
trans” in the packaging process, so not incorporated in the
genome of the resultant particles [41]. These engineered vi-
ruses are thus replication defective and contain less than 10%
(or < 1kB) of the original viral genome; the only protein
expressed by the integrated DNA within the target cell is the
cargo protein of choice—from the transgene cassette. The
tissue tropism of LVs tends to be quite broad, and they have
proven to be less flexible than AAVs, but the engineered
EIAV in current use is fully neurotropic, being pseudo-typed
with the envelope protein of vesicular stomatitis virus (VSV-
G), which facilitates a broad tissue (and species) tropism.
Other pseudo-typing has been used with different tissue tro-
pisms [42, 43], but for fuller tissue specificity, LVs have the
cargo capacity to include tissue-specific enhancers [44], some-
thing not possible in AAVs.
A theoretical concern with LVs is that the genomic integra-
tion that is integral to their function and also provides a po-
tential for oncogenicity. Such oncogenicity has been seen with
some GTs, but only for retrovirus-mediated gene delivery to
bone marrow populations for immunodeficiency disorders
[45–48]. The key difference here from the EIAV technology
is that the viruses employed were not LVs, but γ-retroviruses,
which have a distinct mode of integration into the host DNA
that makes themmore prone to inducing oncogenicity [49]. In
addition, the transduced cells were actively proliferating, rath-
er than postmitotic, and so are probably given a selective
growth advantage, promoting the development of additional
mutations and oncogenicity. Such considerations make it un-
likely that LV transduction of CNS neurons will provoke on-
cogenesis, although some uncertainty around this issue must
remain.
Gene Therapy Strategies
The target of the current GTs for PD is the motor circuitry that
is deprived of dopaminergic innervation as a result of the
degeneration of the nigrostriatal (NS) projection. There are
however several potential approaches by which GT can be
used to manipulate this pathological circuitry, so improving
patient symptoms. The three main strategies are described
below (see also Fig. 1):
1. Gene therapy to modify motor circuitry: circuit modifica-
tion by GT uses gene delivery to a critical node within the
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motor circuitry of the basal ganglia to provide a biological
effect similar to DBS.
2. Gene therapy to synthesize DA: DA-synthetic GT aims to
restore the DA synthesis capacity in the tissue where it is
needed, in this case the putamen—the major target of the
degenerating NS projection.
3. Gene therapy to modify disease: growth factor (GF) GT
uses GFs to boost survival and function of residual NS
neurons, so slowing disease progression in this pathway
and supporting residual DA production.
Each of the approaches has potential benefits and draw-
backs, and all have now been trialled in patients with PD.
For each, AAV and LV vectors might be considered as closely
equivalent options, given that both have demonstrated long-
term expression in humans over periods of years—up to
4 years for LVs in ocular gene transfer of endostatin/
angiostatin for macular degeneration [50], and over 10 years
according to postmortem data on AAVs in PD [42]. AAVs are
though the more established technology, having been used in
the majority of trials to date. LVs have so far been used ex-
clusively for one of two DA-synthetic approaches, but if
regulatable expression becomes useful or necessary in due
course, then they may well find roles in other areas [51].
Gene Therapy to Modify Circuitry
The DA depletion that characterizes PD results in profound
changes in the motor circuit of the basal ganglia and related
structures. These changes derive from DA’s role as a modu-
lator of neuronal activity (neuromodulator), which affects dif-
ferent pathway activities in distinct ways. For example, the
direct and indirect pathways are respectively activated and
inhibited by DA, resulting in loss of the normal balance of
activity between these two pathways as DA levels decline.


























Fig. 1 Rationale for the different gene therapy strategies currently used in
PD, compared with deep brain stimulation. (A) Normal motor circuit
anatomy and activity. (B) In PD, there is degeneration of the nigrostriatal
(NS) projection from the substantia nigra pars compacta (SNc) to the
putamen. This results in abnormalities of motor circuit activity, including
hyperactivity of the STN nucleus. (C) DBS stimulation of the STN in-
hibits STN hyperactivation and so restores normal circuit activity. (D)
Normal motor circuit function can be restored through GT: (a) Circuit
modifying GT uses gene transfer of the enzyme GAD to the STN, so
directly inhibiting STN activity. (b) DA synthetic gene GT replenishes
DA supply within the putamen, so normalizing circuit activity and func-
tion. (c) Growth factor GT exposes axonal terminals of NS projection
neurons within the putamen to GFs, so facilitating transport of such GFs
to the SNc. This may prevent further degeneration of the NS projection
and boost function of residual axonal arbors.
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the circuit, shows heightened synchronized activity in the ab-
sence of DA, with a pattern that is dominated by low frequen-
cy neuronal spiking [52, 53]. This synchronized hyperactivity,
so-called β band activity, is felt to be specifically detrimental
to motor performance, being tightly correlated with some clin-
ical features of PD, including slowness (bradykinesia), stiff-
ness (rigidity), and tremor. The ability of DBS to interfere with
β band activity may be integral to how it achieves its benefi-
cial effects [11] (Fig. 1C).
The use of AAV2 to deliver glutamic acid decarboxylase
(GAD) to the STN is a logical extension of these insights. The
STN has a physiological output that is glutamatergic and
therefore excitatory to its downstream target nuclei. By
transfecting STN neurons with a gene for GAD, which con-
verts the excitatory neurotransmitter glutamate to the inhibi-
tory transmitter gamma-aminobutyric acid (GABA), the out-
put of the STN can in principle be converted from excitation to
inhibition. This is predicted both to dampen activation of STN
target nuclei—the globus pallidus interna (GPi) and substantia
nigra pars reticulata (SNr)—and also, through effects on re-
ciprocal interactions within the STN, to suppress synchro-
nized activity of the nucleus itself. In essence, the strategy
promises to achieve through GT a similar benefit to DBS,
but without the need for long-term implantation of batteries
and wires. The aim of this form of therapy is illustrated in
Fig. 1D(a), and the relevant clinical trials are summarized in
Table 1.
This approach was pioneered by a collaboration between
investigators at Weill College of Medicine at Cornell and a
biotech company Neurologix, and this group were in fact the
first to use GT to treat adult neurological disease. Early pre-
clinical studies in rodents [16, 58], and later in primates [59],
were encouraging, showing correction of clinical deficits and
even a degree of neuroprotection. This data facilitated subse-
quent clinical studies, and a phase 1 safety study of unilateral
STN treatment using viruses carrying a mix of genes for two
GAD isoforms (GAD65 and GAD67) was published in 2007
(NCT00195143) [54]. Three dose cohorts were used in 12
patients with PD with an average disease duration of around
9 years. AAV2-GAD was infused into the STN unilaterally in
an open-label study design. The results showed the procedure
to be well tolerated, with no adverse events (AEs) related to
the intervention. There were also statistically significant
changes in UPDRS scores and FDG-PET signal on the treated
side.
With this encouraging data, Neurologix and the study team
went forward to a phase 2 double-blinded study of bilateral
STN injections, recruiting 45 patients split (23/22) between
sham and a treatment arms (NCT00643890) [55]. Again the
procedure was well tolerated, with no AEs related to treat-
ment. However, this time, in the blinded format, efficacy re-
sults were disappointing. Improvement in the defined OFF
UPDRS part 3 motor scores at 6 months were significant,
but only modest at 23% compared with 12% in the sham
arm. For comparison, the first randomized controlled trial
using DBS showed a 41% improvement in OFF UPDRS part
3 score at 6 months [10]. For this reason, the Neurologix trial
was not considered a resounding success, and Neurologix
later filed for bankruptcy in 2012.
This strategic failure underlines the high bar to success that
exists in the form of STN-DBS, the current gold standard
competitor in this therapeutic space. However, this may not
be the end of the road for STN-GAD therapy, as a subsequent
analysis has emphasized a real and potentially useful effect,
with clinical improvements persistent at 12 months and
matched by measurable and correlatable changes in network
activity as seen with FDG-PET imaging [56, 57, 60]. These
later results have yet to salvage the approach, but the technol-
ogy has now been obtained by another biotech company,
MeiraGTx, and is still currently considered to be one of their
pipeline products for the treatment of PD. Its potential advan-
tage over other GT strategies lies in its relative ease of
Table 1 Summary of circuit modifying GT trials to date









Low dose: 4.5 × 109 vg/STN
Medium dose: 1.4 × 1010 vg/STN
High dose: 4.5 × 1010 vg/STN
Infusion: 45 μl/STN
iMRI—no
Category: phase 1, safety and dosing
Patients: 12 subjects
Disease stage: advanced PD; avg. duration 9 years
Primary: safety. Well tolerated, no AEs
Secondary: improvement in UPDRS, mainly on treated side;










Dose: 4.5 × 1010 vg/STN
Infusion: 45 μl/STN
iMRI—no
Category: phase 2, randomized, sham surgery
Patients: 45 patients—split 22/23 (active/sham)
Disease stage: advanced PD; avg. duration 10.6/12.0 years
Primary: UPDRS scores
Secondary: multiple including 18F-FDG
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administration: the STN is a small and well demarcated target
that functional neurosurgeons target frequently for DBS; cru-
cially, it could be infused with the relevant vector more quick-
ly and completely than the larger putamen (see below).
However, for the same reason, off-target effects may be more
difficult to control.
Gene Therapy to Synthesize Dopamine
Within the basal ganglia, DA is delivered to the striatum by
axonal projections from the substantia nigra (SNc), which thus
regulate striatal function and motor and cognitive perfor-
mance. In the striatum, the main population of striatal output
neurons—medium spiny neurons (MSNs)—are exposed to
DA in both “tonic” and “phasic” modes, with phasic release
being tightly correlated with circuit activity and behavior, and
important for habit learning [66]. Phasic DA responses cannot
be reconstructed by gene delivery to the striatum, but tonic
DA exposure seems sufficient to ameliorate many of the fea-
tures of PD in both patients and animal models.
Replenishment of DA supply through GT is therefore an ob-
vious approach. To date, two vector/cargo combinations have
been employed to achieve resupply of DA to the DA-
denervated putamen. The aim of this therapy is illustrated in
Fig. 1D(b), and the relevant clinical trials are summarized in
Table 2.
AAV2-AADC
The first of the two DA synthetic strategies aims to restore
sensitivity to exogenous levodopa treatment by augmenting
striatal levels of the enzyme aromatic L-amino acid decarbox-
ylase (AADC). AADC is the final step in conversion of levo-
dopa to DA, and its striatal expression within the dopaminer-
gic nerve terminals is lost with disease progression [67, 68].
Thus, although not a dose-limiting step physiologically, its
levels become dose-limiting with disease progression, and
AAV-mediated transfection of AADC into striatal MSNs
should theoretically correct this deficit. Restoring AADC ac-
tivity then allows striatal DA to be synthesized in response to
exogenous levodopa, which must be supplied orally [68, 69].
This strategy has the benefit of retaining some control over the
amount of DA synthesized, via alterations in oral levodopa
dose. A single AADC gene is well within the cargo size of
the AAV vector, and preclinical studies in rodents and parkin-
sonian non-human primates (NHPs) have paved the way for
using AAV to deliver its AADC cargo to patients in the clinic
[70, 71].
The first studies of AADC gene therapy in patients with PD
were performed in California under the sponsorship of the
biotech company Genzyme (NCT00229736) [61, 72]).
Using an AAV2 vector, the group completed a twin-dose
safety study in 10 patients with moderately severe disease
(average disease duration of 11.2 years). Two cohorts of 5
patients were split into low and high doses that equated to
9 × 1010 viral genomes (vg) and 3 × 1011 vg per patient, ad-
ministered via two injection sites at a volume of 50 μl per
putamen. From a safety perspective, the treatment was well
tolerated over the 6 months of the study, although three of the
patients had small intracerebral hemorrhages along the trajec-
tory of the catheter at the time of surgery (two of which were
asymptomatic). Secondary outcomes included clinical assess-
ments in the defined OFF medication state, and these showed
significant (up to 30%) improvements in both cohorts, where-
as diary scores improved in all patients, and levodopa daily
dose was reduced in three of the patients in the low dose
cohort, and all five in the higher dose cohort. There were also
significant increases in 18fluoro-L-m-tyrosine (FMT)-PET
signal in both cohorts, rising to 75% of baseline in the high
dose subjects.
These initial results were encouraging and were also cor-
roborated independently by a group in Jichi University, using
an identical vector and methods [62]. Six subjects received the
same dose as the high dose patients from California, and again
the procedure was well tolerated, with no sustained AEs, al-
though one venous hemorrhage at the site of a cannula inser-
tion produced minor transient motor deficits. Again, there was
an apparent benefit as assessed by a number of secondary
outcomes at 6 months, with a 46% improvement in defined
OFF UPDRS part 3 motor scores and a 56% improvement in
FMT-PET signal.
Due to concerns about tissue (putaminal) coverage, partly
sparked by data from the contemporaneous neurturin (NRTN)
trials (see below), these phase 1 trials were followed by a refined
phase 1 study, again with a primary focus on vector delivery,
dose finding, and safety (NCT01973543) [63]. Now under spon-
sorship of the biotech company Voyager Therapeutics, a novel
delivery technique was introduced which aimed to optimize tis-
sue coverage. This employed a new stepped tip cannula
(SmartFlow, MRI Interventions, Inc.) and a novel surgical
targeting system (SmartFrame and Clearpoint neuro-
navigational system -MRI Interventions, Inc., Irvine, CA), work-
ing in conjunction with the Brainlab software (iPlan Flow).
Intraoperative MRI (iMRI) and the contrast agent gadolinium
(Gd) facilitated visualization of putaminal coverage in the oper-
ating theatre. This in turn allowed the use of higher volumes of
infusate and also flexibility in the number of cannulae employed
(two or three per side), so optimizing coverage. Using this ap-
proach, previous volumes of 100 μl per putamen were shown to
be inadequate, and were therefore increased up to as much as
900 μl per putamen, with viral doses being increased incremen-
tally in 3 cohorts, up to 4.7 × 1012 vg per subject (50 times the
low dose of the original study).
Results again showed the procedure to be well tolerated
[63]. One subject suffered three serious AEs (SAEs)
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consisting of a deep vein thrombosis and pulmonary embolus
and subsequent atrial fibrillation, all of which resolved and
were felt to be linked to the immobility needed for the infusion
rather than the agent itself. In the higher dose cohort,
putaminal coverage was up to 42% by iMRI, with a 79%
increase in baseline 18F-DOPA PET signal. Secondary end-
points included UPDRS part 3 motor ON scores, UPDRS part
3 defined motor OFF scores, Hauser diary entries, levodopa
equivalent dose (LED), and PDQ-39. All of these measures
showed improvements across the three dosing cohorts, with
dose dependency present for all except diary scores. There
were particularly impressive reductions in daily levodopa
equivalent dose (LED), which in the high dose cohort was
similar (at − 41%) to that obtained by DBS. Mild transient
increases in dyskinesia were noted at 1 month, but the therapy
was broadly well tolerated, in particular with no behavioral
AEs.
Although encouraging both in terms of the degree of im-
provement and persistence over the time of the study (up to
36 months), these results do not exclude a significant placebo
effect. Thus, the current status of AAV2-AADC technology is
that Voyager Therapeutics is undertaking a multicenter phase 2
study (RESTORE-1), using a slightly modified virus at a single
dose level, in a sham surgery-controlled trial. A heavy
Table 2 Summary of dopamine synthetic GT trials to date
NCT number, sponsor, and site Virus and dosing Study details and outcomes
NCT00229736
Sponsor: Genzyme






Low dose: 9 × 1010 vg/patient
High dose: 3 × 1011 vg/patient
Infusion: 2 deposits of 50 μl per putamen
iMRI—no
Category: phase 1, safety and tolerability
Patients: total 10 subjects, 5 per dose
Disease stage: advanced PD; avg. duration 13/9.4 years
Primary: safety. Well tolerated. One patient with symptomatic
hemorrhage, almost complete recovery. Two with asymptomatic
hemorrhages









Dose: 3 × 1011 vg/patient
Infusion: 2 deposits of 50 μl/putamen
iMRI—no
Category: phase 1, safety and tolerability:
Patients: 6 patients
Disease stage: advanced PD; avg. duration 10 years
Primary: safety. Well tolerated. One patient with small hemorrhage and
transient symptoms.
Secondary: improvements in UPDRS and 18F-m-tyrosine PET
NCT01973543
Sponsor: Voyager Therapeutics







Low dose: 7.5 × 1011 vg/patient
Medium dose: 1.5 × 1012 vg/patient
High dose: 4.7 × 1012 vg/patient
Infusion: iMRI/SmartFlow, 2 or 3 tracts,
450–900 μl/putamen
iMRI—yes
Category: phase 1, safety /dose finding
Patients: 15 subjects, 5 per dose
Disease stage: advanced PD
Primary: safety. Well tolerated. One patient with three SAEs, due to
immobility during procedure—DVT, PE, AF.
Secondary: improvements in all—putaminal coverage (iMRI);







Refs: not yet published
AAV2-AADC (VY-AADC02)
Putamen, bilateral
Up to 2.5 × 1012 vg/patient
Infusion: 2 or 3 tracts, up
to 900 μl/putamen
iMRI—yes
Category: phase 2, blinded RCT, sham surgery control
Patients: 42 subjects
Disease stage: advanced PD
Primary: safety (multiple, including psychiatric); striatal coverage;











Dose: three dose levels, 1·9 × 107,
4.0 × 107 and 1.0 × 108 transducing units
(TU)/patient
iMRI—no
Category: phase 1, safety and dose finding
Patients: 15 subjects, 3 dose levels.
Disease stage: advanced PD; avg. duration 13.9 years [8–27]
Primary: safety. Well tolerated; no SAEs due to treatment
Secondary: improvements in UPDRS 3 and PDQ-39; modest im-
provements in raclopride-PET, and LED
NCT03720418 (SUNRISE-PD)
Sponsor: Axovant
Site: Paris (France), Cambridge




Refs: not yet published
EIAV-triple enzyme (OXB-102)
Putamen, bilateral
Dose: three dose levels, 4.2 × 106,
1.4 × 107, and 4.2 × 107 TU/patient
Infusion: 3 deposits of 100 μl/putamen
iMRI—no
Category: phase 1/2—safety and dose finding, moving to sham surgery
Disease stage: advanced PD
Patients: 3–4 patients per dose, 3 dose levels
Primary: safety
Secondary: UPDRS, Hauser diaries, PET, dyskinesia rating scale;
Hauser diaries; PDQ-39, SF-36, and clinical global impression
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emphasis in this study is being placed on safety, including
psychiatric parameters, but primary outcomes may now also
include striatal coverage by MRI, F-DOPA PET imaging,
and diary scores. All being well, the company hopes to push
forward towards a phase 3 study in the near future (RESTORE-
2) [73].
EIAV-Triple Enzyme
The direct competitor to the AADC therapy is the more com-
prehensive “triple enzyme” approach [64, 65]. Again, the an-
atomical target is the striatum, but in this format, the viral
cargo encodes all three enzymes required to synthesize DA
from the precursor amino acid tyrosine. These include tyro-
sine hydroxylase (TH), GTP cyclohydrolase 1 (GCH1, an
enzyme required for synthesis of tetrahydrobiopterin, a cofac-
tor for TH), and also AADC. The inclusion of all three en-
zymes is aimed at facilitating a more definitive reduction in
medication doses than the AADC approach. Additionally,
with no reliance on an adequate biodistribution of exogenous
levodopa, the strategy could facilitate a more efficient elimi-
nation of motor fluctuations. Coding for three enzymes is
however beyond the carrying capacity of AAV-based vectors,
and so this strategy has utilized a LV vector initially devel-
oped by the biotech company Oxford Biomedica [74, 75].
Initial preclinical work demonstrated the practicality and
safety of using an EIAV LV for CNS gene therapy in both
rodent and NHP models of disease [41, 75–79]. The first in
human use of a LV gene therapy to the CNS was then under-
taken, initially in Paris and then Cambridge, UK, by Oxford
Biomedica using their ProSavin® vector [64]. Patients had
advanced disease (average duration 13.9 years), and dosing
was between 1.9 × 107 and 1.0 × 108 transducing units (TU)
per patient. Surgical infusion was performed via five tracts per
putamen initially, but this was simplified to three tracts in the
final surgical format. Safety outcomes in the initial 15 patients
showed no AEs related to the agent, whereas secondary mea-
sures of efficacy showed improvements relative to baseline at
6 and 12 months in the UPDRS part 3 motor score (32% and
29%) and also in PDQ-39 (− 4.9 points, − 14.7%) at 6 months.
Dose reductions in LED were however modest, matching
those changes seen on Raclopride PET binding (− 5.2%, −
9.6%, and − 10.1% in low medium, and high dose cohorts).
This good safety record and hints at efficacy serve to rein-
force the AAV data and emphasizes the broad potential for
surgically delivered GTs in PD. The unblinded data from the
LV/ProSavin approach [64] is perhaps slightly less convinc-
ing than for the Voyager AAV-AADC study published more
recently [63], but like the original Genzyme study, the
ProSavin study was a first attempt and has set the scene for
a further dose-finding and safety trial with higher doses of
vector. This new trial, Sunrise-PD, is currently underway
and may produce more convincing effects.
Sunrise-PD addresses concerns of suboptimal production
of the three enzymes through a vector that has been re-
engineered to optimize DA production [80]. Specifically, the
TH gene, already truncated to avoid auto-inhibition, is now
expressed as a fusion protein with GCH1, so optimizing ex-
pression and allowing for a single internal translational initia-
tion site (IRES) upstream of the second cassette that contains
the AADC gene. Published data suggests that DA production
in transfected cells will now be 5–10 times higher than with
the previous version [80]. As with the original trial, delivery of
the vector (OXB-102) is by infusion, but will now rely on 3
injections of 100 μl per putamen (total 300 μl per side).
Sunrise-PD commenced at the end of 2018 and is now spon-
sored by Axovant Gene Therapies. Once dose optimization is
complete, a move towards a planned sham surgery phase is
likely to happen in 2021.
Realistic Competitors for DBS
Although AADC and triple enzyme gene therapies do not rep-
resent a cure for PD, or even a slowing of disease progression,
they do represent a potentially viable alternative to DBS, the
current gold standard for treating motor fluctuations. As de-
scribed above, the target patients in trials to date have been those
with moderately advanced PD and motor fluctuations, which is
exactly the group in which DBS has found its major niche.
Whether there is room for both of these two new gene
therapies in this space, alongside DBS and infusion therapies,
is not clear at present. How things work out is likely to depend
on just how successful each modality is in improving fluctu-
ating motor features in this problematic patient group. The
triple enzyme approach, which is not reliant on a supply of
oral levodopa, has the potential to achieve a greater reduction
in oral medication than AAV2-AADC and a better smoothing
out of motor fluctuations. In practice, how much this
distinction really matters is yet to be understood, and the
AADC approachmay yield a lower risk of uncontrolled motor
or neuropsychiatric side effects, because the DA stimulus can
be regulated not only by viral dose and tissue distribution, but
also by oral levodopa dose after surgery. Moreover, in the
higher dose cohorts in the Voyager/AADC trial, subjects not
only benefited from reduced fluctuations but also managed to
reduce their oral levodopa intake by very significant amount
and still achieve improved OFF medication scores on formal
motor testing [63]. This suggests that increasing AADC en-
zyme levels in the striatum may improve some symptoms
even in the absence of a recent oral levodopa dose (perhaps
by improving utilization of residual endogenous levodopa).
Role of iMRI Imaging
At present, the other distinction between the two approaches is
turning out to be the reliance of the AAV2-AADC approach
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on iMRI to monitor the vector distribution obtained by their
convection enhanced delivery (CED) technology. The
Voyager team has focused heavily on this aspect, using Gd-
iMRI monitoring as a means of optimizing vector delivery at
the time of surgery.
The technique of CED was originally described in the 1990s
[81, 82] and relies on generation of a pressure gradient at the
needle tip that enhances tissue spread of vector by bulk convec-
tive flow rather than by diffusion. It has been pioneered by the
Bankiewicz team and is now in use in both AAV2-AADC and
AAV2-GDNF trials (see below). Using a 1:1 mix of gadolinium
contrast agent (Gd) and viral sample, the distribution of viral
infusate can be accurately monitored in real time using iMRI.
NHP studies have confirmed a tight match between MRI visual-
ization and pathological distribution of vector expression [83],
and needle design has incorporated a shoulder into the device, a
short distance back from the exit point of the needle, to reduce
backflow and optimize the pressure gradient [84].
This strategy promises optimization of effect in individual
patients, but more importantly it may also facilitate refinement
of surgical technique over time. Thus its benefits are already
apparent in enabling safe administration of higher volumes of
infusate than are planned for the Axovant/LV study. Indeed,
such high volumes may well partly underlie the promising out-
come data in the latest unblinded Voyager study [63]. However,
visualization of tissue coverage also promises a greater under-
standing (and avoidance) of off-target effects, which could turn
out to be extremely important, particularly as continuous dopa-
minergic stimulation of ventral striatum carries the risk of un-
wanted neuropsychiatric side effects.
Although the LV strategy has not yet used iMRI to monitor
tissue distribution, it is unclear whether or not this is a true
drawback. There are differences in how the two vectors move
through brain tissue that may make iMRI less useful for LVs
(AAV2 diffuses poorly, so must be convected [83]), and lack
of a need for iMRI technology could boost uptake of the
EIAV-triple therapy technology, in the context that many
DBS centers outside North America do not currently employ
iMRI in their DBS practice. This might give the LV vector a
competitive advantage, at least in the short term. One current
limitation to comparing these two approaches is the lack of
any postmortem data on EIAV vector distribution in humans,
and so the field relies heavily onNHP data. Ultimately, wheth-
er the LV strategy adopts some form of iMRI monitoring in
due course remains to be seen.
Gene Therapy to Modify Disease
Growth Factors in PD
The extensive demonstrations of safety and efficacy of GT in
late PD, by the twin strategies of DA replacement and circuit
modification, is very important for the future of the technolo-
gy in both PD and other CNS diseases. However, in reality,
these approaches only offer a better means of managing motor
features in a disease that is already advanced and irreversible.
Given the wealth of historical data examining DA neuronal
survival, a more ambitious strategy would look to use GT
strategies to slow or halt the DA neuronal loss that underlies
disease progression.
Growth factors (GFs) have a long history of exploration in
PD (reviewed in [89]), having been thoroughly examined in
both cell culture and PD animal models over several decades.
Particularly, promising beneficial effects have been noted for
two related GFs: glial cell line derived neurotrophic factor
(GDNF) and neurturin (NRTN) [90, 91]. Both of these are
able to enhance survival and neurite outgrowth of DA
neurons in vitro and in vivo [92–95], and both can rescue
DA neurons in preclinical models of PD [78, 96–98].
Such work has raised hopes for using these GFs as ther-
apeutic agents in PD, both to slow DA neuronal loss and
to enhance function in the surviving DA neurons and their
axon terminals [99, 100]. The aim of this form of therapy
is illustrated in Fig. 1D(c), and the relevant clinical trials
are summarized in Table 3.
Protein Infusion—GDNF
The first in human use of GFs to treat PD was not through GT,
but via surgical infusion of the recombinant GF protein
(rGDNF) itself, which is relevant to briefly review. A se-
quence of trials were made, starting with the unsuccessful
use of intraventricular rGDNF delivery [101], before moving
on to procedures that targeted the putamen directly. These
initial open-label intraparenchymal infusion studies showed
some promising outcomes [102–104]. However, a random-
ized study, using infusion pump driven delivery of rGDNF
to the putamen, failed to meet its primary trial outcomes at
6–8 months [105].
Based on methodological concerns, additional evidence of
benefit from postmortem studies, and anecdotal longer term
follow-up data on some patients from the initial open-label
trials [106, 107], a revised double blind placebo-controlled
trial was undertaken in Bristol, UK, and the results from this
have been published recently [108, 109]. This trial abandoned
pumps, using instead intermittent (monthly) infusions of
rGDNF, for up to 80 months. A stronger emphasis was also
put on tissue coverage, and a MRI-monitored CED infusion
approach was employed. Although the trial did not meet its
primary end point, improvements in 18F-DOPA PET were
documented, and 95% of the patients receiving rGDNF for
the full 80 weeks gained a meaningful clinical improvement
in one or more of the core outcome measures. Whether this
constitutes a useful outcome is unclear, but the surgical deliv-
ery system employed in this study was complex and not
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without complications, as has also been reported in the new
ongoing trial of recombinant cerebral dopamine neurotrophic
factor (rCDNF) protein being undertaken in Scandinavia
[110]. As such, these recombinant GF protein therapies are
probably best considered as preparing the ground both for
the more tractable genetic approach of GF GTs.
AAV2-NRTN—Ceregene
Despite earlier work using LV-mediated GDNF delivery in
animal models, the first GF to come to the clinic in the format
of a GT was actually NRTN rather than GDNF, and used an
AAV2 vector, rather than LVs. AAV2-NRTN was
manufactured by the Californian biotech company Ceregene,
with their product CERE-120 providing neuronal expression
of NRTN as a pure protein without viral coding sequences
[111]. To enhance secretion, the preprodomain of human
nerve growth factor was used in place of the NRTN sequence,
and preclinical testing showed CERE-120 to be well tolerated,
with persistent gene expression for periods of over 12 months
and minimal biodistribution beyond the target area [111–113]
(reviewed in [114]). Therapeutically, it showed promising ef-
fects on the survival of SNc DA neurons in rodent and NHP
PD models.
Initial clinical studies followed, and a phase 1 study of 12
patients, with an average disease duration of 11 years, found
CERE-120 to be well tolerated (NCT00252850) [85]. This
study was not powered to determine whether the agent had
Table 3 Summary of GF GT trials to date
NCT number, sponsor and
site
Virus and dosing Study details and outcomes
NCT00252850
Sponsor: Ceregene








Low dose: 1·3 × 1011 vg/patient
High dose: 5.4 × 1011 vg/patient
Infusion: 8 × 5μl deposits/side, split
between 4 needle tracks/side
iMRI—no
Category: phase 1, safety and dosing
Patients: 12 subjects
Disease stage: advanced PD; avg. 11 years
Primary: safe and well tolerated
Secondary: no significant benefits in OFF UPDRS3 at 12 months and









Dose: 5.4 × 1011 vg/patient
Infusion: 8 × 5μl deposits/side (40 μl)
4 needle tracks/side, 2 deposits/track
iMRI—no
Category: phase 2, randomized, double-blind, sham-surgery–controlled
Patients: 58 subjects–38/20 in surgery/sham arms
Disease stage: advanced PD; avg. 9.5/10.0 years, in active/sham arms
Primary outcome: nonsignificant improvements over sham surgery in OFF
UPDRS3
Secondary outcome: nonsignificant trends to improvement UPDRS; timed









Putamen and SN, bilateral
Dose: 2.4 × 1011 vg/SNc;
1.0 × 1012 vg/putamen
Infusion: two deposits of 15 μl/SNc; one
deposit of 50 μl in each of 3 putaminal
tracts
iMRI—no
Trial category: phase 2, randomized, double-blind,
sham-surgery–controlled
Patients: 48 patients, 23/25 treated/sham arms
Disease stage: advanced PD; avg. duration 7.8/8.6 years in treatment/sham
arms
Primary: no significant change in OFF UPDRS part 3 at 15 months









Low dose: 4.5 × 1010 vg per putamen
Medium dose: 1.5 × 1011 vg/putamen
High dose: 4.5 × 1011 vg/putamen
450 μl/putamen
iMRI—yes
Trial category: phase 1, safety and dose finding, 4 dose levels
Patients: 25 subjects; three dose levels
Disease stage: > 5 years disease
Primary: safety and tolerability.Well tolerated. Six SAEs, none attributable
to study drug; all resolved
Secondary: Nonsignificant improvements in 18F-F-DOPA PET at
18 months. No significant change in UPDRS, LED at 6/18 months; PET












Trial category: phase 1, safety
Patients: 12 subjects, 2 cohorts
Disease stage: earlier (< 5 years) and later (> 5 years, moderate–severe
disease)
Primary: safety tolerability over 5 years
Secondary: UPDRS, nonmotor scores, and DAT scan changes over
18 months
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either a symptomatic benefit or a later disease-modifying ef-
fect, but even so 18F-levodopa PET findings were a little dis-
appointing, with no clear change in striatal signal.
The real stumbling block was the subsequent blinded study
(NCT00400634), which recruited 38 patients to the active arm
and 20 patients to sham surgery [86]. Notably, the average
disease duration in the recruited participants was 9.5 and
10 years in the surgical and sham arms respectively, and by
this measure, subjects were slightly more advanced than those
in the GDNF protein infusion studies [105, 109]. A viral dose
of 5.4 × 1011 vg per brain was comparable to other
putaminally targeted AAV2 procedures, but this dose was
delivered without MRI guidance, and as eight separate de-
posits, each of 5 μl, split between four needle tracts per hemi-
sphere (total 80 μl). The trial failed to meet its primary end
point of a change in the UPDRS part 3 motor score in the
defined OFF medication state at 12 months with the
intervention.
On the positive side though, the procedure was again well
tolerated—SAEs occurred in both arms, but none were attrib-
utable to the novel therapy. However, a failure to meet the
primary endpoint meant that the therapy as delivered could
not be competitive with the established technology of DBS.
Things could have stopped there, but as with the Bristol
GDNF protein study [109], there were clues in the original
data that a subset of patients might be getting significant ben-
efit, with patients assessed at 18 months demonstrating a sig-
nificant benefit over placebo. This was not the primary end-
point, and the benefit was only seen in a small subset of the
total patients, but this and some additional trends to improve-
ment with surgery in some of the secondary endpoints sug-
gested that modifications to the delivery might yet improve
outcomes over a longer time course (see below).
AAV2-NRTN—Postmortem Data
An important element in this decision to continue trialling this
agent was postmortem data on four patients, who died of
unrelated causes subsequent to receiving the gene therapy,
which lent more insight into the disappointing outcome.
Two of these individuals died within a few months of treat-
ment and two of them about 4 years later, so giving a time
course of transgene effects. There were three main findings
from these pathological studies [115, 116], the first being the
technical issue of poor tissue coverage by the GT within the
putamen. Thus, although putaminal NRTN expression evoked
by the treatment was good and persistent, the volume cover-
age per infusion was less than 20% of total putaminal volume,
which was probably insufficient to provide good clinical
benefit.
The second observation was that dopaminergic denervation
of the striatum was surprisingly advanced even at 5 years into
the disease. Probably at least partly as a result of this, the
enhanced tyrosine hydroxylase (TH) expression evoked by
the NRTN was rather modest and only covered ~ 2% of
striatal area in the short-term cases and 13.4% in the longer
term (4 years) cases. This suggested a resistance to trophic
effect in these patients, albeit one that was partly overcome
with time.
Thirdly, the striatal NRTN expression was not matched by
similar NRTN expression in the SNc as would be expected by
the retrograde transport of GF observed in preclinical models.
This was improved in the two longer term patients but was still
poor even compared with aged animal models and was
matched by deficient transport to other putaminal targets such
as GPi. This suggests a retrograde axonal transport deficit in
patients with PD, which may be specific for certain projec-
tions, as the transport of NRTN from putamen to cortex (via
axon terminals within the putamen) seemed to be largely
intact.
Together, these findings imply that the degenerating hu-
man NS system offers a significantly different environment
for disease-modifying strategies than is apparent in either pre-
clinical rodent or NHP PD models, and that both better tissue
distribution of AAV2-NRTN and more protracted time points
might be needed. More fundamentally, it is difficult to envis-
age a GF working on NS projections that no longer exist, and
data from other groups also suggests that the α-synuclein
pathology of PD may itself impair both axonal transport and
GDNF/NRTN receptor (RET) expression and signalling in the
surviving NS projections [117–119]. This has been debated
[120], as has the extent to which there may be unwanted
detrimental effects of these GFs [121].
AAV2-NRTN—a Revised Attempt
The logical outcome from this pathological data was that
NRTN delivery to relevant tissues still needed to be optimized.
This would require several improvements on existing method-
ology, including larger volumes of infusate, delivery of vector
to both putamen and SNc, and inclusion of earlier stage pa-
tients. Moreover, assessment would need to be done over lon-
ger time points than the 12 months of the original studies.
Revised studies were therefore embarked up on which partly
explored these issues, specifically by reinforcing putaminal ex-
pression of NRTN with co-expression of the same vector in
SNc. This line of investigation required further preclinical stud-
ies, which ultimately concluded in a revised blinded sham con-
trol study that reported in 2015 (NCT00985517 [87]).
Patients in this study now received bilateral doses AAV2-
NRTN to both SNc and putamen, with putaminal doses being
four times the previous dose, and subjects being followed for
between 15 and 24months. However, again the study failed to
hit its primary endpoint of change in defined OFF UPDRS
part 3 motor scores. Notably, given the pathological data,
disease durations for participants in this study were slightly
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shorter than before, at 7.8 years for the treated and 8.6 years
for the sham cohort. As fluctuations are a marker of NS de-
generation, this suggests that denervation of the striatum in
these subjects was probably still profound. One of these sub-
jects has come to postmortem subsequently (8 years after sur-
gery), and this examination confirms that vector-mediated
NRTN expression remains robust even at this time point, with
correlated TH expression, but that the coverage of expressing
tissue was again very limited in extent [122].
Despite its overt failure, post hoc analysis of this trial again
suggested that certain subgroups, in particular those with
shorter disease durations, might show some benefit, backing
up the pathological conclusions. This latter point is a crucial
insight and one that is being tackled in the inclusion criteria of
an upcoming AAV2-GDNF trial being run through the
Universities of Ohio and California.
AAV2-GDNF
On this background, AAV2-GDNF is the last therapy still
standing in the arena of GF GT for PD at present, and recent
reports suggest some hope. Preclinical work suggests that
GDNF may have more powerful neurotrophic effects than
neurturin [123] [98], and successful transduction of putaminal
medium spiny neurons has been shown in both rodent, pri-
mate, and aged primate models with rescue of dopaminergic
projections [124–126].
Following on from these preclinical studies, a phase 1 trial
of 13 patients with moderately severe PD was undertaken
sponsored by the National Institute of Neurological
Disorders and Stroke (NINDS) (NCT01621581) [88, 127].
AAV2-GDNF was delivered by iMRI-CED in 3 dose levels
between 9 × 1010 and 9 × 1011 vg per patient, and the proce-
dure was well tolerated. Gd-iMRI tracking of the infusions
however showed that putaminal coverage (using 450 μl
infusate per putamen) was again limited at only 26%, suggest-
ing that, despite demonstrated improvements in 18F-DOPA
PET signal, further optimization of delivery might be required
in future studies. This conclusion was also reinforced by the
variability in improvement in PET signal; although improve-
ment was seen in 12 of 13 patients, the range of change in
those that improved was wide (between 8 and 130% above
baseline, median 54%), and the other patient experienced uni-
lateral deterioration.
Despite these limitations, the NINDS study has provided
proof of principle evidence, and a second study
(NCT04167540) is now being planned. This new study is
penned to start imminently, based out of the Universities of
California and Ohio, and sponsored by the biotech company
Brain Neurotherapy Bio, Inc. Its twin aims are to assess the
utility of GF GT in a cohort of patients with earlier disease
(less than 5 years) and also to optimize tissue coverage using
iMRI and a novel neurosurgical approach. This uses a
posterior stereotactic trajectory and a single infusion cannula
that should facilitate better coverage of the irregular volume of
the putamen—allowing a “shape-conforming” infusion [128].
The primary endpoint is safety over 5 years, with secondary
endpoints of changes inmotor and nonmotor scores, alongside
DAT scan changes (18 months).
GT with Growth Factors—Still a Viable Option?
Overall, these GF studies have been very valuable, in partic-
ular with respect to our improved understanding of the path-
ological human striatal environment in PD. The good safety
and tolerability profiles of the AAV2 vectors that has emerged
is also important, but the overarching conclusion is that using
GF-mediated GT to rescue the degenerating human NS sys-
tem in PD is unlikely to be a panacea for all patients.
Even so, the potential prize remains substantial, and if a
clear “disease severity threshold” could be drawn, before
which GT could be given with a good prospect of benefit,
then this would still be an important achievement. PD is rela-
tively easy to diagnose, and such a therapy given early (e.g.,
before 5 years) would have the potential to slow disease pro-
gression in this pathway across large numbers of patients, so
ameliorating a large burden of disease that currently carries
very significant impacts on patients, carers, and society.
Unfortunately such a threshold—a measure of responsive-
ness to GF therapy—is likely to vary considerably from pa-
tient to patient (perhaps up to 10 years in some patients) and
may be difficult to assess accurately a priori. However, there is
currently a good prospect that the DA replacement strategies
(AAV2-AADC and LV-triple enzyme) will become important
backup options in later stage patients, alongside the current
mainstay of DBS. By comparison, the circuit modification
approach seems to have faded as an option at present, but its
ease of surgical administration to a small volume target means
that it is still an attractive alternate approach if significant
benefit can be demonstrated.
Growth Factors Long Term
The prospect of treating PD patients early with GF GT is not
only enticing but also carries risks. Short-term side effects of
the GF treatments thus far have been minimal but the longer
term risks are very unclear. NHP data has not so far produced
clear evidence of long-term problems, but potential side ef-
fects, including aberrant sprouting of SN DA neurons, weight
loss, and hyponatremia, have been highlighted in some pre-
clinical work, as well as one of the early trials that delivered
rGDNF into the cerebral ventricles [101, 129, 130].
For these reasons, some attention has switched to looking
at regulatable vectors that could allow the GF stimulus to be
switched off flexibly after transduction—perhaps even
allowing an intermittent GF dosing regimen to be used over
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months and years. This sort of regulation would require addi-
tional gene regulatory sequences and might be difficult to
achieve within the restrictive payload of AAVs. This issue
might drive a move to use LVs for GF therapy in due course,
as these vectors can facilitate regulatable expression in differ-
ent cells systems including the delivery of GFs to the striatum
[131]. However, there remains a good deal of focus on devel-
oping AAVs in novel ways [24], so regulatable AAV technol-
ogy may yet emerge.
Future of Gene Therapy for PD
GT therapy is still in its early days and is an emerging tech-
nology. Several new avenues suggest that the studies de-
scribed above may only be the forerunners of a wider array
of GT options for PD in the future.
Combined Therapies
Although combining GF therapy with DA synthetic GT has
been postulated, it is unlikely to be a useful strategy given that
different disease time points require different therapeutic strat-
egies. By the stage of disease at which DA synthetic treatment
needs consideration, GF GT would be unlikely to work given
the extent of NS degeneration; conversely, early treatment
with GF GT ought to obviate the need for later GT to manage
motor fluctuations.
A more likely scenario is that GF GT will be combined
with, or replaced by, other GT approaches that either promote
responsiveness to GFs or otherwise provide a beneficial
disease-modifying effect. Although systemic (non-GT) treat-
ments along these lines may well be feasible and easier, the
GT approach may still retain some advantages. By
“vectorizing” a treatment to certain neuronal populations
(e.g., NS projection neurons or striatal MSNs), off-target ef-
fects might be minimized and a more potent disease-
modifying effect obtained. Novel approaches along these lines
might include manipulation of downstream pathways from
NRTN/GDNF (e.g., overexpression of the GF receptor
Nurr1), or direct targeting of culprit disease pathways, includ-
ing α-synuclein toxicity [132, 133], and LRRK2 kinase
overactivation [134]. Virally mediated gene inhibition
(RNAi) or editing (CRISPR-Cas9) are two options here
[135], but where PD is seen in the context ofGBA1mutations,
expression of the normally functioning wild-type gene may
prove beneficial [136]. A New York-based biotech company
is already pursuing this latter goal using intracisternal injec-
tion of an AAV9-based vector carrying GBA1, with phase 1
results l ikely to be published in the near future
(NCT04127578 and [137]). Also on the brink of clinical test-
ing is vectorized antibody therapy againstα-synuclein, a tech-
nology that has been previously been developed for treating
HIV infection [138, 139] and which is being pushed in the PD
field by a collaboration between pharma companies Abbvie
and Voyager. Again, an AAV vector is the proposed technol-
ogy [140].
Other Vectors
With the AAV2 and EIAV studies being generally well toler-
ated, there will be a good deal of temptation to stick with
vectors known to be safe. Introduction of a novel vector would
entail starting from scratch with safety studies for any evolv-
ing strategies, but such approaches may offer new potential
advantages. In particular, AAV2 is known to bind to heparan
sulfate proteoglycans (HSPGs), moieties that are abundant on
the neuronal surface and contribute to vector uptake, but
which also limit vector diffusion. Although this has allowed
tight control over vector targeting, arguably this control has
been too tight, contributing also to the limited putaminal dis-
tribution of vector that has led to failed trials. Other AAV
serotypes, such as AAV9, can diffuse more broadly within
neuronal tissue [15], while maintaining neuronal infectivity,
and may well have achieved better putaminal distribution of
vector payload had they been employed. Such vectors, and
modifications of them, may yet come into their own for PD,
in particular for strategies that aim to curtail the spreading
pathology that characterizes the PD brain. Some of these vec-
tors may also allow peripheral (or intrathecal) delivery (see
below).
In Situ Reprogramming
Although the strategy of asking putaminal cells to start mak-
ing DA in situ is easily understood, another option being ex-
plored is a more fundamental reprogramming of endogenous
putaminal cells, converting them directly into TH expressing
neurons. These brand new DA neurons (perhaps converted
from endogenous astrocytes) might be able not only to start
producing DA, but also to sprout an axonal arbor and provide
more efficient DA delivery to striatal cells via synapses. The
technology for this, although more distant than standard gene
therapy, is nevertheless on the horizon, with encouraging data
emerging in animal models [141].
Bypassing the Surgeon
Future nonsurgically delivered therapies may also yet dis-
place these options, particularly if delivery methods are
eased while target specificity is maintained, and any im-
munological issues are side-stepped. One option proposed
is the use of peripherally delivered vector (e.g., via intra-
venous infusion), in combination with targeting to specif-
ic brain regions by local disruption of the blood–brain
barrier (BBB) with focused ultrasound [142]. This could
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be an extremely attractive option for either advanced or
early disease. Indeed, more anatomically diffuse disrup-
tion of BBB can be obtained even more easily pharmaco-
logically [143] and might enable much more widespread
CNS uptake of vector and, with this, more extensive dis-
ease modification.
Summary of GTs in PD
We are currently at an exciting time in the arena of GT for
the PD field. Several therapeutic options are emerging in
parallel as potential treatments for this condition, but with
the safety profile of the technology so far holding, this
bodes well for an even wider array of GT options in the
future. Time will tell which if any of the current and future
candidate GT treatments emerges as useful and practical
therapy and so ends up dominating the therapeutic arena
for PD. It is also possible that GTs could be used synergis-
tically with cell therapies [144].
The Cell Therapy Approach to Treating
PD—the Rationale
The main rationale for the use of cell therapies in PD has been
to replace the lost A9 DA neurons of the SNc—the ones that
are principally affected by the disease process in this condi-
tion. Other approaches have been tried which exploit less de-
fined modes of action—e.g., Spheramine® was trialled as a
cell therapy that was thought to work more through a trophic
and paracrine action [145], in much the same way as the par-
thenogenetic stem cell therapy being trialled at the present
time by ISCO [146]. Nevertheless, the vast majority of ap-
proaches have sought to replace the few hundred thousand
DA neurons that are lost in PD, engrafting new cells in the
striatum where DA normally works. These therapies therefore
are not being used to rebuild the circuitry as originally lost
(since the grafts are placed heterotopically), and nor are they
being used to cure PD—as the underlying disease process
carries on in the PD patient brain and may even involve the
grafted cells themselves (see below). Rather, DA cell therapies
are being used as a symptomatic therapy to better treat the
nigrostriatal dopaminergic aspects of PD, albeit that a core
component of the PD pathology is being repaired in the pro-
cess. Although this approach is restricted in its ambition, it
does have the potential (if it works) to make redundant almost
everything we currently do for PD patients in the clinic, with
drugs and surgery. This is because all current drug and surgi-
cal therapies essentially work on the dopaminergic aspects of
PD, and the complications that these drugs produce arise
through abnormal activation of this pathway (see above).
The Types of Cell Used for Transplantation
There are a number of cell types that have been considered to
be suitable for grafting as DA neuronal replacements (includ-
ing for example, peripheral sympathetic neurons, adrenal
medullary cells, and carotid body cells), only some of which
actually form neurons of the type lost in PD. This is important
as preclinically it has been shown that the A9 neurons are the
optimal DA cells for effecting repair at this site [147], and
other DA cell types work less well, if at all. Many of the other
sources of cells that have been trialled either do not form
neurons (e.g., adrenal medullary cells [148]), or do not form
the DA neurons of the midbrain (e.g., parthenogenetic stem
cell-derived neurons [149]). In this review, we will concen-
trate on the work that has been done with fetal ventral mesen-
cephalic (VM) tissue (that contains the developing
DA neurons of the midbrain) and stem cell (both ES and
iPSC)-derived DA neurons. In terms of these latter cells, some
comment needs to be made at this stage about their relative
advantages and disadvantages.
Human fetal VM (hfVM) tissue is derived from elective
termination of pregnancies and as such brings with it major
ethical issues around abortion. Thus the use of such tissue is
strictly regulated in all countries, but in some it is not allowed
to be used at all for clinical purposes and/or research—
although this can also change over time (e.g., the USA). In
part, this is because of concerns that the adoption of such an
approach may encourage women to have terminations, espe-
cially if they have family members affected by conditions that
may use such tissue for therapeutic gain. In addition, religious
objections are also key arguments raised around not allowing
human fetal tissue from termination of pregnancies to be used,
centering on questions of the potentiality of embryos and the
sanctity of life.
However, in the UK for example, there is no evidence that
using fetal tissue in transplant programs changes practice in
terms of women deciding to have a termination of pregnancy
or not. Furthermore, there are strict guidelines stipulating that
those donating fetal tissue cannot say which programs of work
they want that tissue to be used for, either clinically or for
research. In addition to these ethical problems are the logisti-
cal ones that in order to have enough surviving DA neurons
after grafting, tissue needs to collected from at least 3 fetuses
per side of the brain grafted. This puts major constraints on
having sufficient tissue to graft patients, given that hfVM
tissue cannot be cryopreserved successfully and can only be
stored in hibernation medium for short periods of time (a few
days only) [150]. Thus, in our recent trial using this tissue in
patients with PD (TransEuro), 87 planned transplant opera-
tions were cancelled because of insufficient tissue being avail-
able for grafting [151]. A final major problem with using this
tissue is that the final grafted cell product cannot be standard-
ized as each patient will receive their own unique tissue
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transplant, which also contains many cells of the type not
needed, given only the minority of cells in the developing
VM are of midbrain dopaminergic origin. However, there
are advantages with using this tissue, including that the use
of primary, non-manipulated tissue brings many regulatory
and safety advantages, as well as greater confidence that one
is replacing like with like—namely the DA cells of the mid-
brain that are lost in PD are being replaced with genuine hu-
man midbrain A9 neurons.
The use of human pluripotent stem cells gets around many
of the above problems, especially logistical ones given these
cells can be easily expanded and differentiated in culture and
then cryopreserved [152, 153]. However, such stem cell ther-
apies are still not without problems. Thus with human embry-
onic stem (ES) cells, ethical concerns remain around the fact
that the cell line so derived can only be achieved through
destruction of that embryo. Some have tried to circumvent this
problem using single blastomeres, so in theory side-stepping
the need for embryo destruction [154].
This problem is avoided to some extent with human
iPSC lines, although not completely, as questions of po-
tentiality still exist with any human stem cell (hPS) [155].
In addition, the country of origin of the human stem cell
line also has implications, as lines derived from countries
that have had cases of new variant CJD cannot
currently be used easily in the USA. Given the size of
the US market, this has major consequences on the com-
mercial development of any product derived from such
cells — the investment in and thus development of that
product may be significantly limited. Finally, there are
issues that have yet to be resolved about the genetic test-
ing and variability seen in stem cell lines, and what this
actually means for their safety clinically. Although many
different types of genetic variability have been shown in a
range of cell lines (e.g., hPS cells recurrently acquire and
expand dominant negative P53 mutations) [156, 157], this
also varies as a function of time in culture, and the sig-
nificance of the variability from a safety perspective is
still unknown. The position of the regulatory agencies
on this aspect also remains to be defined.
All of these issues, coupled with the commercialization of
any future stem cell-based therapies for PD, has meant that
many teams are now seeking to derive and use their own hPS
cell line, as this gives them greater control over what that line
can be best employed to treat. This though can make it hard to
extract exact information about the cell being developed for
clinical trialling. However, reassuringly, most modern differ-
entiation protocols mean that the major worry with these cells
of teratoma development is a problem that is more theoretical
than real. In addition, the regulatory agencies now all have
clearer guidelines on what is needed to show that these cells
are acceptable from a safety, biodistribution, and tumorigenic-
ity perspective.
Immunological Issues with Cell-Based
Therapies
The use of cell-based therapies for treating PD brings with it
issues of immunogenicity, as would be the case for any allo-
transplant. One difference for CNS disease is that the brain has
a degree of immunological privilege, and the cells are also not
especially immunogenic given their fetal origin or derivation.
Nevertheless, rejection issues are still important and need to
be considered, as they may have contributed to the lack of
efficacy in the double blind placebo-controlled fetal transplant
trials done in the last part of the twentieth century (reviewed in
[158]).
The brain has long been known to have relative immuno-
logical privilege by virtue of having no professional antigen
presenting cells within it, a limited lymphatic drainage system,
and a blood–brain barrier (BBB). However, of late, it has been
shown that the CNS is actively patrolled by the immune sys-
tem and that a relatively well-developed G lymphatic system
is also present, which means that antigens within the CNS can
be delivered to the peripheral immune system and an immune
response generated [159]. As such, cells placed into the CNS
will likely evoke an immune reaction, especially as the grafted
procedure itself will temporarily disrupt the BBB. Thus, un-
less the cells are autologous, some sort of immunosuppressive
treatment will be needed at least for a time after implantation.
The extent of this immunosuppression will depend in part
on the following factors:
& When the BBB seals up (which is thought to be within a
few weeks for cell suspension grafts [160]).
& When dying cells and fragments from the transplant stop
entering the peripheral immune system and thus being
exposed to the peripheral immune system (which is prob-
ably in the first few weeks only after grafting [161]).
& The immunogenicity of the cells being grafted, both at the
time of grafting and as they mature relative to the host.
For hVM tissue, this last issue has been looked at both
in vitro [162] and in vivo [163, 164], with such work
showing that the tissue can both express major histocompati-
bility (MHC) antigens and invoke an immune response. This
has also been seen with hPSC-derived allografted tissue
in vitro, as well as in NHP studies using matched and mis-
matched stem cell grafts [165]. In this latter study, it also
shown that the rejection response could be abrogated with
tacrolimusmonotherapy [165]. All of this has led some groups
to consider less immunogenic cells—either using an autolo-
gous approach [166], or using a universal cell line where the
major MHC antigens have been engineered out of the cells
[167]. Whether either of these approaches really offers advan-
tages for treating PD remains unproven, as is the case that
autologous iPSCs are really immunologically tolerated when
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grafted back into the donor host [168]. There are though two
other issues that need to be considered with the use
of autologous approaches:
1 The cost of making individualized cell therapies (which
currently in the UK would be in the region of several
million pounds per patient)
2 The risk of promoting any PD pathology in the grafted
cells given they are patient derived (and thus harbor the
same genetic risks for PD) and α- synuclein pathology has
consistently been found in unrelated fetal DAcells 10 years
after grafting [169]
In spite of these possible risks, the first report has been
published of a single patient receiving an autologous iPSC
derived DA cell transplant for their PD [170]. In this case,
the patient had bilateral transplants of cells without immuno-
suppression and responded well symptomatically, although
not on other more objective measures. This case, while show-
ing that this approach was safe, used protocols for making the
DA neurons that might not have been optimal and in addition
there were other controversial aspects to how this transplant
was done [171].
At the present time though, most groups have elected to use
allogeneic cells and immunotherapy after grafting. This latter
regime is typically of the type normally used in other organ
transplants and which to date has been used with fetal tissue
trials in patients with PD without much in the way of compli-
cations [151]. As to exactly what this regime will look like in
future stem cell trials for PD, and for how long it will be given
after grafting, is still to be finalized.
What Has Been Shown with Cell-Based
Therapies to Date?
The initial trials in the early to late 1980s predominantly used
adrenal medullary tissue for which the preclinical evidence
was limited (reviewed in Barker and Dunnett 1991). The con-
clusion of the clinical trial work using this tissue, which was
undertaken extensively across many centers especially in the
USA, was that these transplants offered no real benefit and
were associated with side effects and poor survival [172, 173].
Therefore they were abandoned, especially as more encourag-
ing data was beginning to emerge with the use of hfVM
allografts.
The move to trial hfVM in the clinic came on the back of
robust reproducible preclinical findings in neurotoxic animal
models of PD that had been carried out in many different
laboratories around the world. These studies showed that al-
lografts of the developing VM into rats lesioned unilaterally
with 6-hydroxy-dopamine (6-OHDA) could survive, make
and receive connections from the host brain, release DA,
and restore behaviors to normal in these animals (reviewed
in [174]). This was also shown in NHP, most notably marmo-
sets [175], and it was on this background that patients were
first grafted in the late 1980s and thereafter till the end of the
century.
Although a number of groups took on this early work, the
best studied cohort was a series of PD patients recruited to an
iterative open-label study in Lund Sweden, led by Olle
Lindvall and Anders Björklund, which also included two
MPTP patients from California [176]. All this work involved
grafting patients with relatively advanced PD with hfVM tis-
sue, and following them over extended periods of time both
clinically and with PET imaging of the DA system. This
study, along with other open-label studies showed that trans-
plants of hfVM could:
& survive long term in the human PD brain (e.g., [177]).
& have long-term clinical benefits (e.g., [178]).
& release DA in a physiological way when the graft was
pharmacologically stimulated (e.g., [179]) with re-
activation of motor cortical areas after grafting [180].
& improve quality of life measures not just motor features
(e.g., [181]).
& work as well when placed striatally as when placed in the
striatum as well as the nigra [182].
& not be guaranteed to work in every patient (e.g., [183]).
& acquire the pathology of PD after several years of engraft-
ment (e.g., [184]).
These early studies led to more formal studies being under-
taken in the USA in the early 1990s once federal funding
became available under the Clinton administration for work
using human fetal tissue. These two NIH funded double blind
placebo-controlled studies reported in 2001 and 2003 and
failed to show clinical benefits that satisfied the trials primary
end points [163, 185]. In addition, both trials reported for the
first time severe and disabling graft-induced dyskinesias
(GIDs) some ofwhich required further neurosurgical interven-
tion [186], and more recently, one patient was shown to have a
transplant that did not work clinically despite recovery of
striatal DA innervation at postmortem and on DA imaging
[187]. As a result, the adoption of this approach for treating
patients with PD fell out of favor, especially in light of the side
effects and lack of efficacy compared with the results that
were appearing at this time with DBS [188]. This in effect
led to a moratorium on this therapeutic strategy and debates
around whether cell therapies had any future in PD.
As part of these discussions, a review of the data from all
these trials was undertaken [158, 189], and a number of con-
clusions were drawn, suggesting that this approach may still
have merit, especially given that protocols for making human
stem cell-derived DA cells of an authentic midbrain type were
starting to emerge. These conclusions were that:
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& Those patients that seem to have the highest chance of
benefitting from hfVM grafts tended to be younger with
less advanced disease.
& Patients with extensive striatal DA loss that extended into
the ventral stratum did less well [190].
& Patients who developed GIDs had reported significant
levodopa-induced dyskinesias (LIDs) pre-grafting, but al-
so that the development of GIDs may relate either to a
poor distribution of DA cells across the striatum [191],
or to the grafting of large numbers of 5HT neurons relative
to the DA cells in the transplant [192]—all of which could
be avoided using better preparation and delivery
approaches.
& The use of no immunosuppression in the first NIH study
was associated with low numbers of surviving DA cells at
postmortem, although there may be other reasons for this
relating to the amount of hfVM tissue grafted. In addition,
in the second NIH-funded study, there was a distinct
change in the direction of the clinical response of grafted
patients when their ciclosporin A was stopped 6 months
after surgery. Although the reasons for this remain un-
known, it could relate to a partial graft rejection on stop-
ping the ciclosporin A.
& Clinical improvements could take many years to appear
and thus using primary end points relatively soon after
grafting may miss the maximal benefit of the grafts.
As a result of this, a new trial funded by the EU
(TransEuro) was set up that tried to address many of these
factors in its design. This trial, which grafted its first patient
in 2015 and its last in 2018, will report next year at the earliest,
as the primary end point is the change in the UPDRS part 3
score in the defined OFF stage, 3 years after the second trans-
plant. The lessons learnt from this trial have recently been
published with the hope that this will help in the design of
the next round of stem cell-derivedDA cell transplant trials for
PD [193]. In addition, this article also highlighted why this
therapeutic approach, using this cell source, has no future
from a simple logistical perspective, but may be adapted if a
stem cell source of DA cells can be identified.
In this last respect, in 2011 and 2012, two seminal papers
from the groups of Studer and Parmar published protocols show-
ing that hESC could be converted into authentic DA neurons of
the midbrain type. Theoretically, these could therefore be used
for treating patients with PD in much the same way as hfVM
tissue [194, 195]. Subsequently, it has been shown that this ap-
proach offers major potential therapeutic promise in treating PD,
by virtue of the fact that these DA neurons can:
& Be produced reproducibly, with a midbrain DA pheno-
type, using different starting cell lines [196].
& Be manufactured in the numbers needed for clinical trans-
lation in a GMP compatible fashion [197].
& Be shown to have equivalence to human fVM grafts in
terms of their functional effects in animal models of PD
[198].
& Connect and establish connections appropriately with the
host brain [199, 200].
In addition, grafts of these cells do not form tumors or
contain large numbers of 5HT neurons [201]. As a result,
several academic groups, often in conjunction with pharma
or small Biotech companies, around the world are now mov-
ing this technology towards clinical trials including in Europe,
the USA, and Japan, with the first of these having started with
an iPSC approach in Kyoto in Japan. This work has been led
by Jun Takahashi, based on his preclinical work in parkinso-
nian NHPs, where he showed long-term survival and efficacy
of human iPSC-derived DA cells [202].
All these groups have over the last 5–6 years worked to-
gether as a consortium (GFORCE-PD [193]) to try and ensure
that their respective clinical trials can be better coordinated,
and also to facilitate the exchange of data around preclinical
developments of these stem cell-derived DA cell products
[203]— an approach which we encourage others working on
similar experimental therapies to adopt. These trials, which
were due to start in the USA in 2020 and in Europe in 2021
prior to the corona virus pandemic, have attracted commercial
interest frommajor companies as the potential for this therapy
to transform the natural history of treated PD at an affordable
cost has now been perceived as realistic by many working in
this field.
What Are the Challenges Moving Forward
with This Approach and Where Will It End?
The field of stem cell-based therapies for PD sits at an impor-
tant stage in its development, since it is about to enter clinical
trials where the effectiveness and utility of this therapy will be
revealed, along with its competitiveness—both therapeutical-
ly and commercially. If these early trials prove successful,
then one can imagine that this therapy will be moved to be
trialled in earlier stage patients as there is a logic in doing this
especially in younger onset cases of PD. Ultimately this ther-
apy has the capacity to transform how we treat PD
by obviating the need for many if not all of the therapies
currently given in the clinic to patients with PD for their motor
problems. Although this remains a long way off, the commer-
cial investment in this area does mean that this field is likely to
move faster through phase 2/3 trials than we might imagine.
As to where next, there is great interest in using the tech-
nologies we have described in this review to directly repro-
gram cells in situ without the need to graft cells into the brain
(see above). In other words, can we convert resident glia into
DA neurons and by so doing avoid the practical, ethical, and
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immunological issues that play a role in any cell transplant
grafted into the brain? This is now being explored in animal
models, although to date the results have been modest at best
with little evidence that sufficient DA cells can be generated of
the type needed to reverse the deficits seen in PD [141, 204].
Nevertheless, this whole area is one that is changing every
year as our ability to reprogram cells becomes ever better
and with this the prospect of repairing the PD brain from
within.
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